Self Study - Module 1: Personalizing Hemophilia A Prophylaxis Regimens

Launch Date:
June 04, 2020
Expiration Date:
September 04, 2021
This module reviews hemophilia A classifications and available therapies. It also reviews clinical data surrounding products used for this disease as well as investigational agents.

Jordan A. Shavit, MD, PhD

Associate Professor of Pediatrics
Division of Pediatric Hematology/Oncology
University of Michigan Medical School
CS Mott Children’s Hospital
Ann Arbor, MI

Dr Jordan A. Shavit is Associate Professor of Pediatrics at the University of Michigan and a pediatric hematologist/oncologist at the CS Mott Children’s Hospital in Ann Arbor, Michigan. He earned his medical and doctorate degrees from Northwestern University School of Medicine in Chicago, Illinois. He then completed a residency in pediatrics and a fellowship in pediatric hematology/oncology at the University of Michigan Health System. He is board certified in pediatric hematology-oncology. 

Dr Shavit specializes in the care of pediatric patients with hemophilia, von Willebrand disease and other bleeding disorders, thrombotic disorders, and thrombophilia. He is a member of multiple societies, including the American Society of Hematology, International Society on Thrombosis and Haemostasis, Hemostasis and Thrombosis Research Society, American Society for Clinical Investigation, and American Pediatric Society.

Doris V. Quon, MD, PhD

Medical Oncologist, Sarcoma Oncology Center
Santa Monica, CA
Medical Advisor, Hemophilia Foundation of Southern California
Pasadena, CA
Medical Director, Orthopaedic Hemophilia Treatment Center
Los Angeles, CA

Dr Doris V. Quon is Medical Director for the Orthopaedic Hemophilia Treatment Center (OHTC) in Los Angeles, California, and a medical oncologist for the Sarcoma Oncology Center in Santa Monica, California. She has an active role in coordinating the federally funded Region IX hemophilia activities for the OHTC and is Medical Advisor for the Hemophilia Foundation of Southern California in Pasadena. She earned her medical degree from the University of California, Los Angeles (UCLA) David Geffen School of Medicine. She then completed a residency in internal medicine, a clinical fellowship in hematology/oncology, and a research fellowship in hematology/oncology at the UCLA Medical Center.

Dr Quon cares for individuals with bleeding disorders and the complications of those disorders at the OHTC, the largest treatment center for individuals 14 years and older in Southern California with bleeding disorders. Her research in hemophilia has led to 40 publications in peer-reviewed journals such as Haemophilia, Blood Advances, the European Journal of Haematology, and the Journal of Thrombosis and Haemostasis. She is a member of multiple societies, including the International Society on Thrombosis and Haemostasis, American Society of Hematology, American Society of Clinical Oncology, National Hemophilia Foundation, and the Hemostasis and Thrombosis Research Society.

1.
APPLY safety and efficacy data on therapeutic agents in hemophilia to create personalized treatment plans
2.
UTILIZE strategies to improve adherence during the transition from adolescence to adulthood
3.
IMPLEMENT strategies for managing inhibitors in patients with hemophilia A
4.
RECOGNIZE modifiable and nonmodifiable risk factors for development of FVIII inhibitors

This educational program is jointly provided by the American Academy of CME and Spire Learning.

This program is supported by an educational grant from Genentech, Inc.

 

INSTRUCTIONS ON HOW TO RECEIVE CREDIT

 
There is no fee to participate in this program. In order to receive CME/CE credit, you must complete:
 
• Baseline Assessment
• Modules 1, 2, 3
• Final Assessment 
• Activity Evaluation
 
Your certificate can be printed immediately.

 

ACCREDITATION AND CREDIT DESIGNATION
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and Spire Learning. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physicians: American Academy of CME, Inc., designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the program.

NPs/Nurses: American Academy of CME, Inc., designates this educational program for 1.75 ANCC contact hours (0.9 pharmacotherapeutic contact hours). 

California
Provider approved by the California Board of Registered Nursing, Provider Number CEP16993 for 1.75 contact hours.

 

DISCLAIMER
The opinions expressed in this educational program are those of the faculty and do not represent those of the Academy or Spire Learning. This program is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information. 

OFF-LABEL STATEMENT
This educational program may contain discussion of published and/or investigational uses of therapies that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, participants are encouraged to consult appropriate resources for any product or device mentioned in this program.

Copyright Statement
Copyright © 2020 by Spire Learning, LLC and its Licensors. All rights reserved. No part of this publication or program may be reproduced or transmitted in any form, by any means, without prior written permission of Spire Learning, LLC. Spire Learning, LLC and American Academy of CME, Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication or program, including any claims related to the products, drugs, or services mentioned herein.

LEVELS OF EVIDENCE

Levels of evidence are provided for any patient care recommendations made during this presentation. Level A (randomized controlled trial/meta-analysis): High-quality, randomized controlled trial (RCT) that considers all important outcomes. High-quality meta-analysis (quantitative systematic review) using comprehensive search strategies Level B (other evidence): A well-designed, nonrandomized clinical trial. A nonquantitative systematic review with appropriate search strategies and well-substantiated conclusions. Includes lower-quality RCTs, clinical cohort studies and case-controlled studies with nonbiased selection of study participants and consistent findings. Other evidence, such as high-quality, historical, uncontrolled studies, or well-designed epidemiologic studies with compelling findings, is also included Level C (consensus/expert opinion): Consensus viewpoint or expert opinion Each rating is applied to a single reference in the presentation, not the entire body of evidence on …

CONFLICT OF INTEREST STATEMENT

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this program. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.

EDUCATIONAL PLANNING COMMITTEE

American Academy of CME, Inc.
John Juchniewicz, MCIS, CHCP, and Natalie Kirkwood, RN, BSN, JD: No relevant financial relationships with any commercial interests.

Spire Learning
Asthon Beggs, PharmD, and Shirley Jones, MBA: No relevant financial relationships with any commercial interests.

Jeanne Prater: Employee (spouse): Novo Nordisk Inc; Shareholder (spouse): Johnson & Johnson.

Reviewer
Brenda Riske, RN, MSN, MBA, MPA : No relevant financial relationships with any commercial interests.

 


FACULTY EDUCATORS

Doris V. Quon, MD, PhD
Medical Oncologist, Sarcoma Oncology Center
Santa Monica, CA
Medical Advisor, Hemophilia Foundation of Southern California
Pasadena, CA
Medical Director, Orthopaedic Hemophilia Treatment Center
Los Angeles, CA

Disclosure Statement:
Advisory Board – for marketing purposes: Bayer Corporation; Genentech, Inc; Novo Nordisk
Advisory Board – for scientific information: Bayer Corporation; Genentech, Inc; Novo Nordisk; uniQure
Consultant – for clinical trial design: Genentech, Inc
Promotional Speaker’s Bureau: Bioverativ/Sanofi; Genentech, Inc; Novo Nordisk; Shire/Takeda

Jordan Shavit, MD, PhD
Associate Professor
Pediatric Hematology/Oncology, Pediatrics
C.S. Mott Children’s Hospital
University of Michigan
Ann Arbor, MI

Disclosure Statement:
No relevant financial relationships with any commercial interests.